Online version of MBCT for lingering depression symptoms improves access to care
Patients who stop taking their medication often experience Antidepressant Discontinuation Syndrome (ADS), which includes flulike symptoms, insomnia, nausea, imbalance, sensory disturbances often described as electric shocks or "brain zaps", and hyperarousal.
Older, first-generation antidepressants often come with additional risks for more severe symptoms, including aggressiveness, catatonia, cognitive impairment, and psychosis. Discontinuing any antidepressant also carries a risk for gradual worsening or relapsing of depression and anxiety, as well as suicidal thoughts. Indefinitely medicated
A recent report from the CDC said a quarter of people taking antidepressants had been using them for a decade or more. Rizkalla says this data makes the case that patients and physicians are overly reliant on medication without concern for long-term consequences.
"I think we have a real problem with patient care management, when it comes to prescribing antidepressants," says Rizkalla. "We tend to put patients on an SSRI and more or less forget about them."
She adds that, while relatively safe, antidepressants still carry side effects, including weight gain, sexual dysfunction and emotional numbing. She also urges caution as the evidence for antidepressant risk factors is based on short-term usage, and says there are no sufficient longitudinal studies on the neurologic impact of taking antidepressants for decades.
Rizkalla and her coauthors included the following tapering schedule for varying classes of antidepressants. However, she insists patients consult their physician before and throughout the process to monitor their symptoms and progress. Source:
American Osteopathic Association Journal reference:
Rizkalla, M., et al. (2020) Antidepressant Discontinuation Syndrome: A Common but Underappreciated Clinical Problem. The Journal of the American Osteopathic Association . doi.org/10.7556/jaoa.2020.030 .
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology